Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors.

Brian J Francica Anja Holtz Justine Lopez David Freund Austin Chen Dingzhi Wang David A Powell Franciele Kipper Dipak Panigrahy Raymond N DuBois Chan C Whiting Peppi Prasit Thomas W Dubensky

Published in: Cancer research communications (2023)

Prostaglandin (PGE2) drives tumor progression but the pathway has not been effectively drugged. We demonstrate significantly enhanced immunologic potency and antitumor activity through blockade of EP2 and EP4 PGE2 receptor signaling together with a single molecule.

Keyphrases

single molecule
atomic force microscopy
poor prognosis
living cells
long non coding rna
wild type